Hospital Monopolies Driving Prices, Drop in Prescription Drug Prices, Dormant Tumor Cells and Recurrence Triggers, and Prompting AI for Symptom Self-Diagnosis

Broadcast from KSQD, Santa Cruz on 8-13-2026:

Dr. Dawn opens by reading an anatomy student's elegy to a body donor, reflecting on how modern medical education has moved away from full cadaver dissection toward pre-dissected specimens and models—and what she believes has been lost in that transition.

Dr. Dawn dissects how hospital consolidation has become the primary driver of runaway U.S. healthcare costs. She contrasts a $16,000 knee replacement at Catawba Valley Medical Center with a $40,000 procedure for the same Blue Cross Blue Shield plan an hour away at Asheville's Mission Hospital—a facility formed by the 1998 merger of the town's two acute-care hospitals and later acquired by HCA in 2018. Mission now charges 333% of Medicare rates (versus a 280% benchmark), and state inspectors have issued three "immediate jeopardy" findings since HCA's takeover, consistent with academic findings that hospital care quality drops when competition disappears. She notes that CMS-required price disclosures since 2021 finally make this transparent, and calls for regulatory prevention of hospital mergers—especially not-for-profit to for-profit conversions—in single or two-hospital markets.

Dr. Dawn analyzes the 3.1% year-over-year drop in prescription drug prices reported through July—the sharpest decline since 1963. She attributes most of it to Biden's 2022 Inflation Reduction Act, which partially rescinded George W. Bush-era Medicare Part D restrictions that had statutorily prohibited price negotiation, saving taxpayers roughly $6 billion in the first six months of implementation. Additional contributors include GLP-1 compounding competition, blockbuster drugs losing exclusivity, and Bureau of Labor Statistics methodology that swaps generics into the price index six months after brand patent expiration. She calls for consumer-facing apps that help patients shop hospital prices the same way they shop cars.

Dr. Dawn covers the emerging science of dormant tumor cells—cancer cells that shed from primary tumors even before diagnosis, hide in bone marrow and lymph nodes, and enter a hibernation state (feeding off cellular residue via autophagy) that shields them from chemotherapy targeting rapidly dividing cells. New York researchers have identified proteins by which lung macrophages actively reinforce dormancy, but immune disruption from COVID-19, influenza, aging, and chronic stress can trigger reactivation. She emphasizes lifestyle protection for cancer survivors: min